DaVita Inc. (DVA), a leading provider of kidney dialysis services in the U.S., continues to draw investor interest despite recent regulatory scrutiny and shifting reimbursement dynamics. The stock has shown modest gains year-to-date, but underlying operational metrics suggest growing pressure on margins.
- DaVita serves 87,200 active patients across 3,360 U.S. dialysis centers
- 2025 revenue totaled $12.4 billion, with adjusted EBITDA margin at 17.3%
- Capital expenditures rose to $487 million in 2025
- Stock trading range: $178–$194 per share (March 2026)
- Forward P/E ratio of 14.7, below healthcare sector average
- Next earnings report scheduled for mid-May 2026
DaVita Inc. (DVA) remains a focal point in the healthcare sector, particularly among investors tracking specialty medical services. As of early March 2026, the company reported 87,200 patients under active treatment across its network of 3,360 dialysis centers, with total revenue for the prior fiscal year reaching $12.4 billion. These figures underscore its dominant market position, holding approximately 25% of the U.S. dialysis market share. However, operational challenges are mounting. In the fourth quarter of 2025, DaVita's adjusted EBITDA margin declined to 17.3%, down from 19.1% in the same period the prior year. This contraction reflects increased costs related to labor, supply chain logistics, and compliance with new CMS (Centers for Medicare & Medicaid Services) reporting mandates. Additionally, the company’s capital expenditure for facility upgrades and digital infrastructure reached $487 million in 2025, signaling continued investment pressure. The stock has traded within a narrow range over the past six months, hovering between $178 and $194 per share. Analysts have issued mixed ratings, with 18 out of 32 recommending 'Hold' and 10 maintaining 'Buy' ratings. The company’s forward price-to-earnings ratio stands at 14.7, below the healthcare sector average of 16.3, which may present a valuation opportunity for long-term investors. Investors should monitor upcoming quarterly earnings, expected in mid-May 2026, for updated guidance on patient growth, reimbursement changes, and margin trends. Regulatory developments, particularly around federal dialysis payment adjustments, could also influence sentiment and capital allocation strategies.